Neurol. praxi. 2016;17(4):236-239 | DOI: 10.36290/neu.2016.049
Strategy initiation of treatment for multiple sclerosis
- MS centrum při Neurologickém oddělení KZ a.s. &ndash, Nemocnice Teplice o. z., Teplice
Multiple sclerosis is a chronic, disabling disease of the central nervous system with involvement of the inflammation and neurodegeneration.
Treatment should be started shortly after the diagnosis of a clinically isolated syndrome or definite multiple sclerosis
in the fulfillment of the requirement of dissemination of lesions in time and space according to the McDonald diagnostic criteria.
The clinical course is heterogeneous and therefore it is necessary to consider the optimal treatment strategy for a particular
patient. It is always appropriate to assess the available prognostic markers, and on this basis decide which medication to choose
first. For highly active form of the disease it is possible to indicate an induction therapy. It is necessary to consider a number of
other circumstances, e.g. the risk of treatment adherence, planned pregnancy, and others. When treatment is ineffective, therapy
must be escalate. Drugs with comparable effect can be reversed due to poor tolerance. The aim of treatment is a state of NEDA
(no evident disease activity).
Keywords: multiple sclerosis, start of treatment, escalation of treatment, NEDA
Published: August 1, 2016 Show citation
References
- Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2015; 29(3): 207-220.
Go to original source... 
Go to PubMed... - Filippi M, Rocca MA, Perego E. Benefit of early treatment with glatiramer acetate: MRI results from the 5-yearprospectively planned follow up in patients with clinically isolated syndrome enrolled in the PreCISe study. Presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Gothenburg, Sweden, October 13-16, 2010.
- Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers. 2013; 35(6): 687-99. Go to original source... Go to PubMed...
- Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases. 2015; 3(7): 545-55. Go to original source... Go to PubMed...
- Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015; 4(4): 329-333. Go to original source... Go to PubMed...
- Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014; 122: 343-369. Go to original source... Go to PubMed...
- Evans C, Tam J, Kingwell E, Oger J, Tremlett H. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther. 2012; 34: 341-50. Go to original source... Go to PubMed...
- Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009; 15(10): 1175-1182. Go to original source... Go to PubMed...
- Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol. 2014; 122: 15-58. Go to original source... Go to PubMed...
- Lazibat I, Nevajda B, Grahovac G, Brinar VV. Should MS be treated by escalation or induction therapy? Coll Antropol. 2014; 38(1): 385-393. Go to PubMed...
- Lublin FD, Reingold SC, Cohen JA, Cutter GR, S?rensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83: 278-286. Go to original source... Go to PubMed...
- Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015; 8(6): 274-293. Go to original source... Go to PubMed...
- Narula S, Hopkins SE, Banwell B. Treatment of pediatric multiple sclerosis. Curr Treat Options Neurol. 2015; 17(3) :336. Go to original source... Go to PubMed...
- Plavina T, Subramanyam M, Bloomgren, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014; 76(6): 802-812. Go to original source... Go to PubMed...
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69: 292-302. Go to original source... Go to PubMed...
- Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A. Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Mult Scler. 2015; 21(13): 1713-1722. Go to original source... Go to PubMed...
- Reuter F, Zaaraoui W, Crespy L, Faivre A, Rico A, Malikova I, Soulier E, Viout P, Ranjeva JP, Pelletier J, Audoin B. Frequency of cognitiveimpairment dramatically increases during the first 5 years of multiplesclerosis. J Neurol Neurosurg Psychiatry. 2011; 82(10): 1157-1159. Go to original source... Go to PubMed...
- Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. The naturalhistory of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010; 133(7): 1914-1929. Go to original source... Go to PubMed...
- S?rensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C. EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis. Guidelines on use of anti-IFN-? antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-? antibodies in multiple sclerosis. Eur J Neurol. 2005; 12: 817-827. Go to original source... Go to PubMed...